Sign In
Buy PACB
$1.45
-0.180 (-11.04%)
At Close: Jun 05, 2026
Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript
09:04pm, Thursday, 07'th Nov 2024
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian
Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
08:31pm, Thursday, 07'th Nov 2024
The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates
07:15pm, Thursday, 07'th Nov 2024
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.27 per share a year ago.
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
04:03pm, Thursday, 07'th Nov 2024
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a priv
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
10:35pm, Wednesday, 06'th Nov 2024
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing
The Schall Law Firm Encourages Investors With Losses To Join An Inquiry Into Pacific Biosciences of California Inc For Fraud
11:00am, Monday, 04'th Nov 2024
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
The Schall Law Firm Encourages Investors To Join An Inquiry Into Pacific Biosciences of California Inc For Securities Fraud
11:00am, Saturday, 02'nd Nov 2024
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
07:16pm, Thursday, 31'st Oct 2024
Pacific Biosciences of California (PACB) reachead $2.17 at the closing of the latest trading day, reflecting a +0.46% change compared to its last close.
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep
10:13am, Wednesday, 30'th Oct 2024
BOSTON , Oct. 30, 2024 /PRNewswire/ -- Volta Labs™, a genomics applications company, announced today that it has joined the PacBio Compatible program, further expanding the partnership between Volt
New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation calling, and expands support for multiomics New l
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
The Schall Law Firm Encourages Investors To Join An Inquiry Into Pacific Biosciences of California Inc For Securities Fraud
11:00am, Saturday, 26'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program
09:05am, Tuesday, 22'nd Oct 2024
MENLO PARK, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Ons
LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
